07-12-2012, 04:21 PM
Current management CHRONIC MYELOID LEUKEMIA - CP
CHRONIC MYELOID LEUKEMIA.pptx (Size: 3.34 MB / Downloads: 66)
Chronic myelogenous leukemia is a clonal hematopoietic disorder caused by an acquired genetic defect in a pluripotent stem cell.
The disease usually envolves into an accelerated phase that often terminates in acute phase
Introduction- CML
Incidence :1.6 - 2 per 100,000
Accounts for 15% of all leukaemia in adults
Median age : 66 years
All age groups, including children, can be affected
slight male predominance (2.2:1.3)
PATHOGENESIS
The discovery of the Philadelphia (Ph) chromosome in 1960 made CML the first human neoplasm to be characterized by a consistent cytogenetic marker.
Clinical Features
Most common presenting symptoms of CML are related to anemia, splenomegaly, and increased cell turnover. Include
fatigue,
left upper quadrant pain,
abdominal distention or discomfort,
early satiety,
weight loss, and
night sweats.
Baseline Prognostic Factors
Phase of Disease
CML blast crisis (5 - 10% cases in the first 2 yrs after diagnosis),
the annual progression rate increased to 20 - 25%.
To guide patient management, various prognostic scales have been developed to predict the probability of disease progression.
Relative Risk (RR)
Sokal
Hasford